Semaglutide Shows Promising Results in Reducing Knee Arthritis Pain in Obese Patients

A recent study reveals significant pain reduction and improved mobility in patients using the weight-loss drug, potentially influencing future treatment approaches.

• The study, published in the New England Journal of Medicine, involved approximately 400 participants with knee osteoarthritis and obesity across 11 countries.
• Participants who received semaglutide injections lost an average of 14% of their body weight, significantly reducing knee pain compared to those on a placebo.
• The drug, marketed as Ozempic and Wegovy, could potentially delay or negate the need for knee replacement surgery by alleviating pain through weight loss.
• Semaglutide's pain relief was comparable to that of opioid drugs, highlighting its potential as a non-surgical treatment option for knee osteoarthritis.
• While the study shows promise, concerns remain about the long-term use of semaglutide, including cost and weight regain if the medication is discontinued.

3 Articles

NBC News Stat News Nature